Vertex has reported positive phase 2b data for its kidney disease prospect inaxaplin, boosting its efforts to expand beyond the population targeted in a pivotal trial.
Vertex has reported positive phase 2b data for its kidney disease prospect inaxaplin, boosting its efforts to expand beyond the population targeted in a pivotal trial.